Translating R&D innovation into healthy pipelines and successful drug launches is R&D’s ultimate aim – and often an elusive one, but two of Britain’s biggest drug companies agree that controlled risk may be the key.
Mene Pangalos, Executive VP at AstraZeneca, and Hal Barron, Chief Scientific Officer and President, Research & Development at GlaxoSmithKline sat down at the 2018 FT Global Pharmaceutical and Biotechnology Conference in London to discuss the ups and downs, triumphs and travails of pharma R&D at their respective companies.
Mene Pangalos, Executive VP at AstraZeneca, and Hal Barron, Chief Scientific Officer and President, Research & Development at GlaxoSmithKline sat down at the 2018 FT Global Pharmaceutical and Biotechnology Conference in London to discuss the ups and downs, triumphs and travails of pharma R&D at their respective companies.
